Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for XXXX .

@entity1 @entity3118 @entity2132 @entity1583 @entity1863 @entity166
Different rabbit polyclonal antilymphocyte globulins (ATGs) are used in allogeneic hematopoietic stem cell transplantation (alloHSCT) to prevent @entity2132 ( @entity2132 ). We compared 2 different ATGs in alloHSCT after reduced intensity conditioning (RIC) for @entity1583 . We reviewed 30 alloHSCT for @entity1583 performed between 2007 and 2010 with @entity3118 and i.v. @entity1863 as conditioning regimen. @entity1 alternatingly received Thymoglobulin or ATG-F. Median followup was 3.3 (2.5-4.5) years. Adverse events appeared to occur more frequently during Thymoglobulin infusion than during ATG-F infusion but without statistical significance (P = 0.14). There were also no differences in 3-year overall survival (OS), disease-free survival (DFS), relapse incidence, and transplant related mortality (TRM) in the Thymoglobulin versus ATG-F group: 45.7% versus 46.7%, 40% versus 33.7%, 40% versus 33.3%, and 20% versus 33.3%. The same held for graft failure, rejection, @entity166 , immune reconstitution, and acute or chronic @entity2132 . In @entity1 transplanted for @entity1583 after RIC, the use of Thymoglobulin is comparable to that of ATG-F in all the aspects evaluated in the study. However due to the small number of @entity1 in each group we cannot exclude a possible difference that may exist.
